These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 32350398)

  • 1. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
    Rassy E; Pavlidis N
    Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
    Olivier T; Fernandez E; Labidi-Galy I; Dietrich PY; Rodriguez-Bravo V; Baciarello G; Fizazi K; Patrikidou A
    Cancer Treat Rev; 2021 Jun; 97():102204. PubMed ID: 33866225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer of Unknown Primary in the Molecular Era.
    Kato S; Alsafar A; Walavalkar V; Hainsworth J; Kurzrock R
    Trends Cancer; 2021 May; 7(5):465-477. PubMed ID: 33516660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
    Hayashi H; Kurata T; Takiguchi Y; Arai M; Takeda K; Akiyoshi K; Matsumoto K; Onoe T; Mukai H; Matsubara N; Minami H; Toyoda M; Onozawa Y; Ono A; Fujita Y; Sakai K; Koh Y; Takeuchi A; Ohashi Y; Nishio K; Nakagawa K
    J Clin Oncol; 2019 Mar; 37(7):570-579. PubMed ID: 30653423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic challenges of patients with carcinoma of unknown primary.
    Rassy E; Pavlidis N
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):775-783. PubMed ID: 32779501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
    Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
    Pentheroudakis G; Greco FA; Pavlidis N
    Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.
    Conway AM; Mitchell C; Kilgour E; Brady G; Dive C; Cook N
    Br J Cancer; 2019 Jan; 120(2):141-153. PubMed ID: 30580378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
    Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
    EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
    Dermawan JK; Rubin BP
    Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer.
    Economopoulou P; Mountzios G; Pavlidis N; Pentheroudakis G
    Cancer Treat Rev; 2015 Jul; 41(7):598-604. PubMed ID: 26033502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
    Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
    Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
    Lorkowski SW; Dermawan JK; Rubin BP
    Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of various techniques/platforms with critical evaluation of each.
    Agwa E; Ma PC
    Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.
    Ma W; Wu H; Chen Y; Xu H; Jiang J; Du B; Wan M; Ma X; Chen X; Lin L; Su X; Bao X; Shen Y; Xu N; Ruan J; Jiang H; Ding Y
    Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38343328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
    Zaun G; Borchert S; Metzenmacher M; Lueong S; Wiesweg M; Zaun Y; Pogorzelski M; Behrens F; Schildhaus HU; Virchow I; Kasper S; Schuler M; Theurer S; Liffers S
    Eur J Cancer; 2024 Mar; 200():113540. PubMed ID: 38316065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives for targeted therapies in cancer of unknown primary site.
    Pentheroudakis G; Pavlidis N
    Cancer Treat Rev; 2006 Dec; 32(8):637-44. PubMed ID: 17046164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
    Greco FA
    Curr Treat Options Oncol; 2013 Dec; 14(4):634-42. PubMed ID: 23990214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
    Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.